Blog

Dec 18, 2024, 12:15

BIG against breast cancer – Some Big updates from the San Antonio Breast Cancer Symposium conference

BIG against breast cancer shared on LinkedIn:

“Last week, the San Antonio Breast Cancer Symposium conference brought together experts from around the world in San Antonio to discuss the latest advancements in breast cancer research! Our team members, Virginie Sarah Adam – Scientific Director at BIG, and Carmela Caballero – Senior Medical Advisor at BIG, were there, soaking in valuable insights to shape the future of breast cancer treatment.

Some BIG updates were shared at the event, including on:

OLYMPIA: New results from the OlympiA trial show one year of treatment with the targeted drug olaparib improves long-term survival in women with high-risk, early-stage breast cancer with mutations in BRCA1 or BRCA2 genes. 10 years after the first patient was included we see that adding olaparib to standard treatment in early-stage inherited breast cancer cuts the risk of women dying by 28% and the risk of coming back by 35%.87.5% of patients who were treated with the drug were still alive compared with 83.2% of those who were given the placebo pills.

SUPREMO: The primary analysis of the SUPREMO trial indicates with high precision that radiation of the chest area following breast removal surgery in patients with 1-3 positive nodes or node-negative with other risk factors with modern multidisciplinary management has no impact on length of life after diagnosis and doesn’t make a meaningful difference in the chance of cancer returning to the chest area.

MINDACT: When researchers looked closely at HER2-low breast cancers, they found these cancers aren’t all the same. They vary in their genetic makeup, their risk levels, and how they respond to treatment. These results may influence future clinical trials with new agents for treatment for HER2 low early breast cancer.

DECRESCENDO: Great results were found in this exploratory analysis when treating early-stage breast cancer before surgery using a combination of drugs that didn’t include anthracyclines (a type of chemotherapy drug that can affect the heart). The treatment worked very well for patients whose breast cancer with HER2-positive, HR-negative, node-negative who showed a complete response.”

BIG against breast cancer - Some Big updates from the San Antonio Breast Cancer Symposium conference